S. Esker

发表

Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy.

J. Albano, H. Tilson, D. Seekins, 2012, AIDS patient care and STDs.

Resveratrol as a Supplemental Therapeutic in Cardiovascular and Metabolic Syndromes: A Critical Review

S. Mousa, A. Banerjee, T. Simone, 2009 .

Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.

K. Mounzer, R. Ebrahimi, E. Dejesus, 2010, AIDS patient care and STDs.

Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals

P. Tebas, J. LaFleur, A. Bress, 2018, Infectious Diseases and Therapy.

Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans Risk Modification by Concomitant Antiretrovirals

P. Tebas, J. LaFleur, A. Bress, 2017, Journal of acquired immune deficiency syndromes.

Intravenous gamma-globulin: clinical applications in pediatric care.

A. Senner, A. M. Bolinger, R. Knapp, 1990, Journal of pediatric nursing.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

B. González-Farré, T. Pascual, M. Espinosa-Bravo, 2022, Annals of Oncology.

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

A. Prat, P. Villagrasa, B. González-Farré, 2021, Frontiers in Oncology.

Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy.

S. Johnston, B. Chu, T. Juday, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.

Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.

B. González-Farré, D. Sellami, J. M. Ferrero-Cafiero, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.